Advertisement

Topics

Moderate-to-Severe Plaque Psoriasis - Biotech, Pharma and Life Science Channel

14:59 EST 23rd January 2019 | BioPortfolio

Psoriasis is a chronic, immune disease that affects the skin. It occurs when the immune system sends out faulty signals that speed up the growth cycle of skin cells. Psoriasis affects up to 1.8 million people in the UK,ix approximately 20 percent of whom have moderate-to-severe plaque psoriasis.Psoriasis can occur on any part of the body and is associated with other serious health conditions, such as diabetes and heart disease. The most common form of psoriasis, plaque psoriasis, appears as raised, red patches covered with a silvery white buildup of dead skin cells.

News Articles [90 Associated News Articles listed on BioPortfolio]

Human medicines European public assessment report (EPAR): Stelara, ustekinumab, Psoriasis,Arthritis, Psoriatic,Crohn Disease, Date of authorisation: 15/01/2009, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Stelara, ustekinumab, Psoriasis,Arthritis, Psoriatic,Crohn Disease, Date of authorisation: 15/01/2009, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Remsima, infliximab, Arthritis, Psoriatic,Spondylitis, Ankylosing,Colitis, Ulcerative,Psoriasis,Crohn Disease,Arthritis, Rheumatoid, Date of authorisation: 10/09/2013, Revision: 14, Status: Authori

Human medicines European public assessment report (EPAR): Remsima, infliximab, Arthritis, Psoriatic,Spondylitis, Ankylosing,Colitis, Ulcerative,Psoriasis,Crohn Disease,Arthritis, Rheumatoid, Date of a...

T Cell Specific Surface Glycoprotein CD28 TP44 or CD28 Pipeline Review, H2 2018 [Report Updated: 13112018] Prices from USD $3500

T Cell Specific Surface Glycoprotein CD28 TP44 or CD28 Pipeline Review, H2 2018SummaryT Cell Specific Surface Glycoprotein CD28 TP44 or CD28 CD28 is a proteins expressed on T cells. It costimulates ...

Human medicines European public assessment report (EPAR): Otezla, apremilast, Arthritis, Psoriatic,Psoriasis, Date of authorisation: 15/01/2015, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Otezla, apremilast, Arthritis, Psoriatic,Psoriasis, Date of authorisation: 15/01/2015, Revision: 6, Status: Authorised

Global Autoimmune Drugs Market 2018-2022 | Market Dominance by TNF- α Inhibitors to Boost Growth | Technavio

The global autoimmune drugs market is expected to post a CAGR of over 8% during the period 2018-2022, according to the latest market research report by Technavio. This press...

Competitor Landscape: Psoriasis [Report Updated: 31102018] Prices from USD $6400

Competitor Landscape: PsoriasisSummarySociable Pharma's Treatment Landscape' contains evaluations of ongoing development activities within the Psoriasis PsO market, analysis of current potential futu...

Competitor Landscape: Psoriasis [Report Updated: 31102018] Prices from USD $5440

Competitor Landscape: PsoriasisSummarySociable Pharma's Treatment Landscape' contains evaluations of ongoing development activities within the Psoriasis PsO market, analysis of current potential futu...

Akaal Pharma Pty Ltd Announces Licensing Agreement for its First-in-Class, Topical Spingosine-1-Phosphate-1 (S1P1) Receptor Modulator for Atopic Dermatitis and Psoriasis

Akaal Pharma Pty Limited (Akaal Pharma) today announced that it has entered into a licensing agreement for Akaal Pharma’s First-in-Class, topical Spingosine-1-Phosphate-1 (S1P1)...

Human medicines European public assessment report (EPAR): Humira, adalimumab, Spondylitis, Ankylosing,Arthritis, Juvenile Rheumatoid,Uveitis,Colitis, Ulcerative,Psoriasis,Arthritis, Psoriatic,Crohn Disease,Arthritis, Rheumatoid, Date of authorisation: 07/

Human medicines European public assessment report (EPAR): Humira, adalimumab, Spondylitis, Ankylosing,Arthritis, Juvenile Rheumatoid,Uveitis,Colitis, Ulcerative,Psoriasis,Arthritis, Psoriatic,Crohn Di...

Exicure Announces Top-line Patient Data for Phase 1 Inflammation Program in Psoriasis

-- First-in-human results in patients with mild-to-moderate psoriasis show significant improvements in clinical scores with no drug-related adverse events -- Exicure, I...

Companies [27 Associated Companies listed on BioPortfolio]

FotoFinder Systems

Founded in 1991 the German company is specialized in skin cancer diagnostics by means of Automated Total Body Mapping, digital dermoscopy, in hair diagnostics, psoriasis documenta...

Akaal Pharma Pty Limited

Akaal Pharma is a private clinical-stage, Australian biotech company focused on advancing the clinical development of its internally discovered topical and oral small molecule dru...

Luma Therapeutics

Based in Silicon Valley, Luma Therapeutics is a privately held medical technology company committed to developing innovative and convenient therapies for the millions of people ar...

LEO Pharma A/S

LEO Pharma is a globally, leading pharmaceutical company within Dermatology and Critical Care. We maintain a strong focus on developing, manufacturing and marketing safe and efficacious drugs for tre...

Ra Medical Systems, Inc.

Ra Medical Systems was founded in 2002 and is a commercial-stage medical device company leveraging its advanced excimer laser-based platform for use in the treatment of dermatolog...

Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion d...

Arrien Pharmaceuticals

Arrien Pharmaceuticals is a targeted therapeutics drug discovery and development company. Arrien applies its proprietary fragment-based FIELDS drug discovery technology to targ...

Tiziana Life Sciences plc

Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology. The C...

Santalis Pharmaceuticals, Inc.

Santalis Pharmaceuticals, Inc. is a wholly-owned subsidiary of TFS Corporation, Ltd. (ASX: TFC). Santalis, and its sister company, ViroXis, were acquired by TFS in July 2015 and a...

Ziarco Pharma Ltd.

Ziarco is a clinical-stage biotechnology company developing innovative therapeutics targeting dermatological and inflammatory diseases. ZPL-389, the Company’s lead compound, ...

Clinical Trials [707 Associated Clinical Trials listed on BioPortfolio]

Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris

Comparison of the efficacy of LEO 90100 foam with Dovobet® ointment in the treatment of psoriasis in Japanese subjects.

Comparison of Scalp Microbiome of the Psoriasis and Seborrheic Dermatitis Patients

A sterile swap specimen taken from the scalp of the patients with psoriasis vulgaris or seborrheic dermatitis and the volunteer control group will be examined in our study. The examples of...

This Trial is a Randomised, Multicentre, Investigator-blind, Vehicle and Comparator-controlled, Parallel-group Trial With the Purpose of Evaluation Efficacy, Safety and Convenience of the MC2-01 Cream

This trial is a randomized, investigator-blind, multicentre, vehicle- and comparator-controlled, parallel-group trial with the purpose of evaluating the efficacy, safety and convenience of...

Study to Assess the Safety and Tolerability of PBF-1650 in Healthy Volunteers.

Single center, randomized, double-blind, placebo-controlled clinical study to assess the safety and tolerability of PBF-1650 in order to obtain the Maximum Tolerated Dose (MTD).

Analysis of Non-Invasively Collected Microneedle Device Samples From Mild Plaque Psoriasis for Use in Transcriptomics Profiling

The purpose of this study is to collect skin biopsies and non-invasive microneedle device samples from participants with mild chronic plaque psoriasis vulgaris to use for transcriptomics p...

Characterization of Lipoprotein Composition and Function in Pediatric Psoriasis Before and After Treatment

This study will assess differences in inflammatory proteins, lipoprotein composition, cholesterol efflux and HDL-proteome in moderate-to-severe pediatric psoriasis who at baseline begin sy...

A Study to Test BI 655130 in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis

To evaluate efficacy, safety, and tolerability of BI 655130 compared to placebo in patients with Generalized Pustular Psoriasis (GPP) presenting with an acute flare of moderate to severe i...

An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis

This Phase 3 multicenter, randomized, placebo-controlled, double-blind study is designed to evaluate the efficacy and safety of apremilast in subjects with moderate to severe genital psori...

A Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Subjects With Manifestations of Plaque Psoriasis and Impaired Quality of Life.

This is a Phase 4, multi-center, randomized, placebo-controlled, double-blind study of the impact of apremilast on quality of life, efficacy, and safety in subjects with manifestations of ...

APACHE Cohort (A Psoriatic Arthritis CoHort)

Psoriatic arthritis (PsA) is a chronic inflammatory rheumatic disease, belonging to the wide spectrum of spondyloarthritis, but with the particularity to be associated with personal psoria...

PubMed Articles [344 Associated PubMed Articles listed on BioPortfolio]

Increase Risk of Multiple Sclerosis in Patients with Psoriasis Disease: An Evidence of Observational Studies.

Psoriasis, a common chronic inflammatory disease, increases the risk of developing multiple sclerosis (MS), but evidence for this outcome is still unclear. However, we performed a meta-analysis of rel...

Mesenchymal stem cells in psoriatic lesions affect the skin microenvironment through circular RNA.

Psoriasis is an autoimmune skin disease. Our previous studies revealed abnormal immune regulation of skin mesenchymal stem cells (S-MSCs) in psoriatic lesions. Circular RNA (circRNA) molecules were re...

Population Pharmacokinetics of Brodalumab in Patients with Moderate to Severe Plaque Psoriasis.

Brodalumab is a fully human monoclonal antibody targeting the IL-17 receptor A leading to an inhibition of the biological effect of IL-17A, IL-17F, IL-17A/F heterodimer, IL-17C and IL-17E isoforms. It...

A novel approach to outpatient clinic management.

I read with great interest the study by Khoury et al in the BJD on the safety of patient-initiated care consultations (PICC) for psoriasis patients, though has wider implications for all patients with...

A Novel Desensitization Protocol for Infliximab hypersensitivity in a 13-Year Old Patient with Pustular Psoriasis.

Drug hypersensitivity reactions to infliximab have been reported in pediatric patients. At times, these patients may need infliximab administration in spite of hypersensitivity. However, only a few re...

Polymorphisms associated with anti-TNF drugs response in patients with psoriasis and psoriatic arthritis.

Psoriatic arthritis (PsA) has been classified as an inflammatory musculoskeletal disease with a strong genetic background. Although anti-TNF drugs are effective for PsA and moderate-to-severe psoriasi...

Spanish Validation of the GEPARD Questionnaire for the Detection of Psoriatic Arthritis in Argentinian Patients with Psoriasis.

Psoriatic arthritis (PsA) is preceded by psoriasis in approximately 80% of cases. Dermatologists are pivotal for early detection. It is important to have simple tools that allow the detection of PsA i...

Willingness to pay for medical treatments in chronic diseases: a multicountry survey of patients and physicians.

The objective was to investigate factors influencing patients' willingness to pay (WTP) and physician's views on the cost of therapy for two contrasted chronic diseases, chronic heart failure and psor...

The Absence of Evidence is Evidence of Non-Sense: Cross-Sectional Study on the Quality of Psoriasis-Related Videos on YouTube and Their Reception by Health Seekers.

Approximately 80% of internet users access health information online and patients with chronic illnesses especially rely on internet-based resources. YouTube ranks second among the most accessed websi...

Association Between Psoriasis and Dementia: A Population-Based Case-Control Study.

Dementia is a syndrome that involves the deterioration of several higher mental functions in advanced age, and psoriasis is an autoimmune disease characterized by skin plaque. Epidemiological studies ...

Medical and Biotech [MESH] Definitions

A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.

A topical anti-inflammatory glucocorticoid used in DERMATOSES, skin allergies, PSORIASIS, etc.

A glucocorticoid used topically in the treatment of DERMATITIS; ECZEMA; or PSORIASIS. It may cause skin irritation.

An anthracene derivative that disrupts MITOCHONDRIA function and structure and is used for the treatment of DERMATOSES, especially PSORIASIS. It may cause FOLLICULITIS.

A humanized monoclonal antibody that binds to IL-12 and IL-23 and is used as a DERMATOLOGIC AGENT in the treatment of patients with plaque PSORIASIS who have not responded to other therapies.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Psoriasis
Psoriasis is a common skin condition affecting 2-3% of the population of the United Kingdom, where the skins replacement process is sped taking 2-6 days instead of the usual 21 - 28 days for the replacement of skin cells. Patients experience an accumulat...

Wound management
Anything that breaks the skin is a wound because when the skin is broken, there's a risk of germs getting into the body and causing an infection. Follow and track Wound Care News on BioPortfolio: Wound Car...